Skip to main content
Premium Trial:

Request an Annual Quote

New NHGRI Sequencing Targets Include Eight New Mammals

NEW YORK, March 15 (GenomeWeb News) - The National Human Genome Research Institute today announced three new priorities for the Large-Scale Sequencing Research Network.

 

The highest priority project will analyze 48 human DNA samples donated for the International HapMap project for structural variations larger than the already-identified SNPs.

 

A second plan will add high-density genome sequencing to existing draft sequences of rhesus macaque, marmoset, and orangutan DNA. NHGRI said it would add other organisms to the list of index species for high-density sequencing.

 

The third plan is to sequence the genomes of eight new mammals at low-density draft coverage. The mammals to be sequenced at two-fold coverage will be chosen from the following species: dolphin, elephant shrew, flying lemur, mouse lemur, horse, llama, mole, pika, kangaroo rat, and tarsier.

 

NHGRI will choose the eight mammals based on "the availability of high-quality DNA samples, the organisms' promise as biomedical models, and the presence of unique, innovative biological processes that may have contributed to the human genome over the course of evolution."

 

Sequencing efforts will be carried out by the five centers of the Large-Scale Sequencing Research Netowrk: Agencourt Bioscience, Baylor College of Medicine, the Broad Institute, the Venter Institute, and Washington University School of Medicine.

 

The complete list of organisms and their sequencing status can be seen here.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.